Addiction/dependence:
Indications for: TRANXENE
Symptomatic relief of acute alcohol withdrawal.
Adult Dosage:
First 24hrs (Day 1): initially 30mg, followed by 30–60mg in divided doses. Second 24hrs (Day 2): 45–90mg in divided doses. Third 24hrs (Day 3): 22.5–45mg in divided doses. Day 4: 15–30mg in divided doses. Then gradually reduce daily dose to 7.5–15mg; discontinue therapy as soon as condition is stable. Maximum total daily dose: 90mg. Avoid excessive reductions in the total amount of drug given on successive days.
Children Dosage:
<9yrs: not recommended.
TRANXENE Contraindications:
Acute narrow-angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
TRANXENE Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Use in depressive neuroses or in psychotic reactions: not recommended. Monitor for the emergence or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior. Renal or hepatic impairment. Monitor CBCs, LFTs during prolonged use. Assess patient’s risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Reevaluate periodically. Drug or alcohol abusers. Elderly. Debilitated. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: not recommended.
TRANXENE Classification:
Benzodiazepine.
TRANXENE Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiation of CNS depression with alcohol and other CNS depressants (eg, hypnotics, barbiturates, narcotics, phenothiazines, MAOIs, or other antidepressants).
Adverse Reactions:
Drowsiness, dizziness, GI disorders, nervousness, blurred vision, dry mouth, headache, mental confusion, insomnia, rash, fatigue, ataxia, genitourinary complaints, irritability, diplopia, depression, tremor, slurred speech, hypotension, abnormal hepatic and renal tests, decreased hematocrit; withdrawal reactions.
Drug Elimination:
Renal (62–67%), fecal (15–19%). Half-life: ~2 days.
Generic Drug Availability:
YES
How Supplied:
Tabs—100
Anxiety/OCD:
Indications for: TRANXENE
Anxiety.
Adult Dosage:
Usually 30mg daily in divided doses or may administer initially at 15mg as a single daily dose at bedtime; adjust gradually in range 15–60mg daily. Elderly, debilitated: initially 7.5–15mg daily in divided doses.
Children Dosage:
<9yrs: not recommended.
TRANXENE Contraindications:
Acute narrow-angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
TRANXENE Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Use in depressive neuroses or in psychotic reactions: not recommended. Monitor for the emergence or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior. Renal or hepatic impairment. Monitor CBCs, LFTs during prolonged use. Assess patient’s risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Reevaluate periodically. Drug or alcohol abusers. Elderly. Debilitated. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: not recommended.
TRANXENE Classification:
Benzodiazepine.
TRANXENE Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiation of CNS depression with alcohol and other CNS depressants (eg, hypnotics, barbiturates, narcotics, phenothiazines, MAOIs, or other antidepressants).
Adverse Reactions:
Drowsiness, dizziness, GI disorders, nervousness, blurred vision, dry mouth, headache, mental confusion, insomnia, rash, fatigue, ataxia, genitourinary complaints, irritability, diplopia, depression, tremor, slurred speech, hypotension, abnormal hepatic and renal tests, decreased hematocrit; withdrawal reactions.
Drug Elimination:
Renal (62–67%), fecal (15–19%). Half-life: ~2 days.
Generic Drug Availability:
YES
How Supplied:
Tabs—100
Seizure disorders:
Indications for: TRANXENE
Adjunct therapy in partial seizures.
Adult Dosage:
Initially 7.5mg three times daily; may increase by max 7.5mg weekly. Max 90mg/day.
Children Dosage:
<9yrs: not recommended. 9–12yrs: initially 7.5mg two times daily; may increase by max 7.5mg weekly. Max 60mg/day.
TRANXENE Contraindications:
Acute narrow-angle glaucoma.
Boxed Warning:
Risks from concomitant use with opioids. Abuse, misuse, and addiction. Dependence and withdrawal reactions.
TRANXENE Warnings/Precautions:
Increased risk of drug-related mortality from concomitant use with opioids. Use in depressive neuroses or in psychotic reactions: not recommended. Monitor for the emergence or worsening of depression, suicidal thoughts/behavior, and/or unusual changes in mood or behavior. Renal or hepatic impairment. Monitor CBCs, LFTs during prolonged use. Assess patient’s risk for abuse, misuse, addiction prior to and during therapy. Avoid abrupt cessation. Withdraw gradually. Reevaluate periodically. Drug or alcohol abusers. Elderly. Debilitated. Neonatal sedation and withdrawal syndrome; monitor neonates exposed during pregnancy or labor. Pregnancy (esp. late stage). Nursing mothers: not recommended.
TRANXENE Classification:
Benzodiazepine.
TRANXENE Interactions:
Increased sedation, respiratory depression, coma, and death with concomitant opioids; reserve use in those for whom alternative treatment options are inadequate; if needed, limit dosages/durations to minimum and monitor. Potentiation of CNS depression with alcohol and other CNS depressants (eg, hypnotics, barbiturates, narcotics, phenothiazines, MAOIs, or other antidepressants).
Adverse Reactions:
Drowsiness, dizziness, GI disorders, nervousness, blurred vision, dry mouth, headache, mental confusion, insomnia, rash, fatigue, ataxia, genitourinary complaints, irritability, diplopia, depression, tremor, slurred speech, hypotension, abnormal hepatic and renal tests, decreased hematocrit; withdrawal reactions.
Drug Elimination:
Renal (62–67%), fecal (15–19%). Half-life: ~2 days.
Generic Drug Availability:
YES
How Supplied:
Tabs—100
